Literature DB >> 3130258

Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values.

M Palmér1, S Jakobsson, G Akerström, S Ljunghall.   

Abstract

Among 16,401 subjects attending two health screenings, in 1969 and 1971, 176 showed hypercalcaemia on both occasions, i.e. serum calcium values above 2.60 mmol l-1. The prevalence of hypercalcaemia increased in women with advancing age and occurred in close to 3% of those above the age of 60, whilst in men it was found in less than 0.7% in all age groups. The mean serum calcium concentration in women above the age of 50 was significantly higher than in men. This observation could at least partly explain why hyperparathyroidism (HPT) is more often diagnosed in females. Only nine persons were initially referred for neck exploration. Most of the others were not even notified of the biochemical disturbance and thus it was possible to study the serum calcium values in an unattended cohort until follow-up after 14 years. In the hypercalcaemic patients there was little or no increase in serum calcium during these years. In no patient did the serum calcium level rise above 3.0 mmol l-1. Altogether, 24 patients from the initial cohort were subsequently operated on for primary HPT but there were only two further cases of verified HPT, which developed during the follow-up period, in those who had been clearly normocalcaemic at the health surveys. In conclusion, hypercalcaemia, presumably caused by primary HPT, is common but apparently develops slowly and with little risk of a progressive rise of serum calcium concentrations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3130258     DOI: 10.1111/j.1365-2362.1988.tb01163.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  23 in total

Review 1.  Parathyroidectomy for asymptomatic primary hyperparathyroidism (PHPT): is it worth the risk?

Authors:  J Rastad
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

Review 2.  Primary hyperparathyroidism: pathophysiology and impact on bone.

Authors:  A Khan; J Bilezikian
Journal:  CMAJ       Date:  2000-07-25       Impact factor: 8.262

3.  Thiazide therapy and severe hypercalcemia in a patient with hyperparathyroidism.

Authors:  P Strong; S Jewell; J Rinker; D Hoch; L Crapo
Journal:  West J Med       Date:  1991-03

4.  Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism.

Authors:  E Lundgren; E Szabo; S Ljunghall; R Bergström; L Holmberg; J Rastad
Journal:  BMJ       Date:  1998-09-26

5.  Prevalence of hypercalcemia in hospitalised patients: effects of "correction" for serum albumin values.

Authors:  V Carnevale; M Pipino; M Antonacci; C Checchia; V D'Alessandro; M Errico; A Greco; A Varriale
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

6.  Determinants of serum calcium in men and women. The Tromsø Study.

Authors:  R Jorde; J Sundsfjord; K H Bønaa
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 7.  Primary hyperparathyroidism.

Authors:  John P Bilezikian; Natalie E Cusano; Aliya A Khan; Jian-Min Liu; Claudio Marcocci; Francisco Bandeira
Journal:  Nat Rev Dis Primers       Date:  2016-05-19       Impact factor: 52.329

8.  Sestamibi scanning and minimally invasive radioguided parathyroidectomy without intraoperative parathyroid hormone measurement.

Authors:  Richard E Goldstein; Dean Billheimer; William H Martin; Ken Richards
Journal:  Ann Surg       Date:  2003-05       Impact factor: 12.969

9.  Molecular classification of parathyroid neoplasia by gene expression profiling.

Authors:  Carl Morrison; William Farrar; Jeff Kneile; Nita Williams; Yiwen Liu-Stratton; Alan Bakaletz; Micheala A Aldred; Charis Eng
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

10.  Primary hyperparathyroidism: epidemiology, diagnosis and clinical picture.

Authors:  S Ljunghall; P Hellman; J Rastad; G Akerström
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.